In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Cardiac resynchronisation therapy: hot news?-heart failure - Title: Cardiac resynchronisation therapy: hot news?-heart failure

Cardiac resynchronisation therapy (CRT) is now established as effective in Heart failure management. However, despite the numerous trials and recently updated guidelines, uncertainty remains regarding the selection of patients in subgroups not so extensively studied. This session dealt with a number of these issues.
Heart Failure (HF)

CRT: What is the hot news

Prof Auricchio showed compelling data from the MILOS study examining the use of CRT in AF patients. It is apparent that Av nodal ablation is required in the majority of cases to ensure optimal benefit from CRT. In the group with a pace and ablate strategy symptomatic improvement, reversed remodelling and survival were comparable or better than in the SR group receiving CRT.

Whilst current trials have generally recruited patients younger than the normal heart failure population, Dr Lamp observed the potential needs and benefits of CRT in the more elderly group. On reviewing the data from the Italian registry and her own data from Bad Oeynhausen, Dr Lamp showed that the symptomatic benefit was equal in the elderly group compared with the younger population. The impact on survival was less marked as would be expected provoking a discussion on the appropriatness of CRT-D in this population.

The role of CRT-D v CRT-P was taken up by Dr Lozano. He showed that whilst no formal study has adequately addressed the issue the weight of evidence supports the additional benefit of the combined device.

Prof Blanc reviewed the potentially deleterious effect of right ventricular pacing on ventricular function and summarised the trials so far on upgrading existing devices. Although there is no randomised data the general opinion remains that in those with deteriorating function up grade to CRT should be considered.


Benefits of CRT are likely to extend beyond the currently recommended guidelines. Current small studies will hopefully be reinforced with the results of the larger on going trials.




Cardiac resynchronisation therapy: what is the hot news? Clinical Seminar
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.